RCS - Eco Animal Health Gp - Head of Global R&D

ECO Animal HealthAnnouncement

01/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251001:nRSA5057Ba&default-theme=true

RNS Number : 5057B  Eco Animal Health Group PLC  01 October 2025

1 October 2025

 

 

ECO Animal Health Group plc
(''ECO" or the "Company")

 

Head of Global R&D

 

ECO Animal Health (AIM: EAH), a rapidly growing global animal health company
with a portfolio of marketed veterinary products and a maturing proprietary
R&D pipeline, confirms that Hafid Benchaoui, Head of Global R&D, will
be leaving ECO Animal Health to pursue a new opportunity in the companion
animal health industry.

 

The Company is making good progress towards recruiting a new Head of Global
R&D, and Hafid will remain in place until 21 October to ensure an orderly
handover of his responsibilities. ECO Animal Health continues to benefit from
a highly experienced senior R&D team, and all developments within the
Company's R&D pipeline remain on track.

 

The Board would like to take this opportunity to thank Hafid for his
contribution to ECO Animal Health and wish him the best in his future
endeavours.

 

The Company will provide further updates in due course.

 

-Ends-

 

Contacts

                                                                020 8447 8899

 ECO Animal Health Group plc

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott

 Jessica Hodgson

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Philip Davies

 Sam Butcher

 Panmure Liberum (Joint Broker)                                 020 3100 2000

 Emma Earl

 Will Goode

 Mark Rogers

 Rupert Dearden

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

 

 

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

 

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

 

Our lead product, Aivlosin(®) is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

 

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAWPUQWBUPAGRU